ACM-CpG是一种纳米粒子投送的癌症治疗,早期显示有望在没有严重副作用的高级固态肿瘤中启动免疫反应。 ACM-CpG, a nanoparticle-delivered cancer therapy, showed early promise in activating immune responses in advanced solid tumors with no serious side effects.

ACM Biolabs报告,通过纳米粒子平台向有先进固态肿瘤的患者提供TLR9抗原剂的实验性癌症治疗ACM-CpG试验第一阶段试验早期取得积极成果。 ACM Biolabs reports positive early results from a Phase 1 trial of its experimental cancer therapy ACM-CpG, a TLR9 agonist delivered via a nanoparticle platform, in patients with advanced solid tumors. 在0.25毫克的低剂量下经管肌肉内剂量,治疗显示没有严重的副作用,并引发了强烈的免疫反应,在最低剂量水平的3名病人中,有2名在8个月的时间里保持了稳定的疾病。 Administered intramuscularly at doses as low as 0.25mg, the treatment showed no serious side effects and triggered strong immune responses, with two of three patients at the lowest dose level maintaining stable disease for eight months. 该疗法证明有可能激活以前“冷”肿瘤中的免疫反应,这是癌症治疗中的一个关键挑战。 The therapy demonstrated potential to activate immune responses in previously "cold" tumors, a key challenge in cancer treatment. 这次试验在新加坡国家癌症中心进行,并得到新加坡工业协调基金的支持,目前正在对甲型CPG头部和颈部、肺部、膀胱和肾癌进行评估。 The trial, conducted at Singapore’s National Cancer Centre and supported by Singapore’s Industry Alignment Fund, is evaluating ACM-CpG in head and neck, lung, bladder, and kidney cancers. 该公司总部设在新加坡,正在利用其用于肿瘤学、传染病和炎症的聚合脂性混合纳米粒子平台开发下一代免疫疗法。 The company, based in Singapore, is developing next-generation immunotherapies using its polymer-lipid hybrid nanoparticle platform for oncology, infectious diseases, and inflammation.